Clinical trials: Neoplasm Malignant
Metastatic Melanoma
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma
The purpose of this multicenter study is to examine whether the proposed randomized treatment regime results in a significantly longer survival time and higher quality of life than any additionally applied multiple chemotherapy…
- Trial name
- NCT00226473
- Testing
- Cisplatin, Vindesine, Dacarbazine (drugs)
- Where
- 13 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Dermatologic Cooperative Oncology Group
Advanced Cancer, Advanced Solid Tumor
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of BGB-B3227, a humanized immunoglobulin G1 (IgG1) antibody.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT06540066
- Testing
- BGB-B3227, Tislelizumab, Chemotherapy
- Where
- 12 sites in United States, China and 1 more
- Volunteers
- 35 people
- Sponsor
- BeiGene
Rectal Cancer
Rectal Washout in Transanal Total Mesorectal Excision and Presence of Intraluminal Malignant Cells
The study aims to assess the existence of intraluminal malignant cells and the appropriate fluid volume needed to perform rectal washout during transanal total mesorectal excision (taTME) for rectal cancer.
- Trial name
- NCT04730102
- Testing
- Rectal washout
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Slagelse Hospital
Ovarian Cancer, Fallopian Tube Cancer
Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse
This study will look at the efficacy and safety of weekly administration of paclitaxel (Taxol®) in monotherapy compared to paclitaxel in combination with topotecan or carboplatin in patients with ovarian cancer in early relapse.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Malignant Tumor of Peritoneum
- Trial name
- NCT00189566
- Testing
- Paclitaxel, Topotecan, Carboplatin
- Where
- France
- Volunteers
- 165 people
- Sponsor
- ARCAGY/ GINECO GROUP
Head and Neck Squamous Cell Carcinoma, Extranodal Extension
Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer
Extranodal extension (ENE) refers to the spread of head and neck squamous cell carcinoma (HNSCC) outside the lymph nodes. It is a well-known factor that indicates a poorer prognosis and outcome for patients who have undergone…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Extranodal Extension, Human Papilloma Virus Related Carcinoma
- Trial name
- EPIC-iENE DATA (NCT05936502)
- Testing
- Extranodal extension
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 3,500 people
- Sponsor
- Head and Neck Cancer International Group
Multiple Myeloma and Plasma Cell Neoplasm
Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of tocladesine in treating patients who have recurrent or…
- Trial name
- NCT00004902
- Testing
- tocladesine
- Where
- United States
- Sponsor
- Northwestern University
Malignant Melanoma
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients
The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine.
- Trial name
- NCT00306553
- Testing
- CYT004-MelQbG10
- Where
- 2 sites in Switzerland
- Sponsor
- Cytos Biotechnology AG
Lung Neoplasm
Single-port, Two-port Versus Three-port VATS on Non-small Cell Lung Cancer
In china, the incidence and death rate of lung cancer is 48.32 per 100 000 person-years and 39.27 per 100 000 person-years, respectively, the highest in malignant tumor.
- Trial name
- NCT02992353
- Testing
- Three-port pulmonary resection surgery, Single-port or two-port surgery
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Neoplasm Female
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
This study is a prospective, open, multi-center, single arm trial. The treatment group will receive six cycles of docetaxel, carboplatin combined with Inetetamab and Pyrotinib before surgery.
- Trial name
- neoPICD (NCT06234137)
- Testing
- Docetaxel, Carboplatin, Inetetamab
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Wang Ouchen
Endometrial Carcinoma, Prostate Carcinoma
Screening and Staging of Benign vs Malignant Pelvic Abnormalities
This study evaluates whether newly developed non-FDA approved image processing techniques [Adaptive Image Reconstruction (AIR Recon) Deep Learning (DL) and Sonic DL] can provide improved quality and decreased time compared to…
- Trial name
- NCT07407959
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Metastatic Malignant Neoplasm to Brain
Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases
Brain metastases are the most common brain tumors in adults. It is estimated that around 10-30% of cancer patients would develop brain metastases during the course of their illness.
- Trial name
- NCT04801342
- Testing
- Conformal Whole Brain Radiotherapy with Unilateral Hippocampal Avoidance, Conformal Whole Brain Radiotherapy with Bilateral Hippocampal Avoidance, Memantine Hydrochloride
- Where
- Taiwan
- Volunteers
- 72 people
- Sponsor
- National Taiwan University Hospital
Colorectal Neoplasms Malignant, Neoplasm, Metastatic
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial
Primary endpoint: objective response rate Secondary endpoints: progression-free survival (PFS), overall survival (OS) and adverse events.
- Trial name
- BOND-4 (NCT07722754)
- Testing
- Cetuximab, Irinotecan, Bevacizumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Neoplasms, Circulating Tumor Cells
Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device
Circulating tumor cells (CTCs) in peripheral blood originate from breast cancer (primary and metastatic lesions) shedding. Utilization of CTCs as novel and noninvasive tests for diagnosis confirmation, therapy selection, and…
- Trial name
- NCT04239105
- Testing
- Microfluidic and Raman spectrum
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Cancer
Remote Electronic Patient Monitoring in Oncology Patients
The goal of this research is to study an intervention, which the investigators call "Remote Electronic Patient Monitoring," that entails vital sign data (enabled with smart algorithms for notification) and patient-reported…
- Trial name
- NCT04086251
- Testing
- Gaido
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Gaido Health
Neoplasm Malignant
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
Primary Objective: To evaluate the safety and tolerability of SAR245409 tablets administered once or twice a day in patients with solid tumors or lymphoma.
- Trial name
- NCT01596270
- Testing
- SAR245409
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Sanofi
Melanoma (Skin)
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
This randomized phase II trial is studying how well carboplatin, paclitaxel, and bevacizumab work when given with or without everolimus in treating patients with malignant melanoma that has spread from where it started to other…
- Trial name
- NCT00976573
- Testing
- bevacizumab, carboplatin, everolimus
- Where
- 310 sites in United States
- Volunteers
- 149 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Malignant Solid Tumor
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors.
- Trial name
- RaPTR-101 (NCT07293754)
- Testing
- RPTR-1-201, PD-1 / PD-L1 monoclonal antibody
- Where
- 12 sites in United States, Ireland and 2 more
- Volunteers
- 150 people
- Sponsor
- Repertoire Immune Medicines
Prostatic Neoplasm, Prostate Cancer
Prostate Cancer Genetic Risk Evaluation and Screening Study
This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI…
- Conditions
- Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation
- Trial name
- PROGRESS (NCT05129605)
- Testing
- Prostate cancer screening
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Massachusetts General Hospital
Mastectomy, Lymphadenectomy
Use of Microporous Polysaccharide Hemispheres in Breast Cancer Patients Undergoing Mastectomy
You should know that your participation in this study is voluntary and that you may decide NOT to participate. If you decide to participate, you may change your decision and withdraw your consent at any time, without altering…
- Conditions
- Mastectomy, Lymphadenectomy, Breast Neoplasm Malignant Female, Breast Surgery
- Trial name
- NCT06824831
- Testing
- Patients receive microporous polysaccharide hemospheres., Patients DO NOT receive microporous polysaccharide hemospheres.
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Melanoma
A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c
Recombinant human GM-CSF herpes simplex virus injection (OrienX010) is a genetically engineered from Chinese patients oral separation of wild type 1 herpes simplex virus (HSV) as the carrier insert GM-CSF gene therapy drug.After…
- Trial name
- NCT03048253
- Testing
- OrienX010
- Where
- China
- Volunteers
- 30 people
- Sponsor
- OrienGene Biotechnology Ltd.